
Index

- accidents 7, 32
 - see also* traffic deaths
- ACE inhibitors 290
- Adam, Taghreed 46–61
- addiction 62
 - see also* drug use
- adolescence *see* young people
- adult day care 298
- advertising, direct to consumer 306–14
 - and agency relationships 309–10
 - care-seeking effect 309
 - and chronic illness 310
 - consumer reaction 310–11
 - historical background to 306–8
 - impact of 311–12
 - literature on 308–9, 310–12
 - and Medicaid spending 312–13
 - and Medicare 313
 - moral hazard 309
 - prescribing patterns 312
 - price elasticity 310
- Afghanistan
 - contracting-out 252, 256
 - public health intervention 55
- Africa
 - internet access 167
 - public health intervention 55, 58
- ageing 19, 20, 33
 - disability rate 297
 - and distributional judgements 383–4, 385
 - and health subsidies 115–16
 - mortality rate 297–8
 - and risk adjustment 279, 280, 282
 - see also* retirement
- AIDS 55, 251, 252, 479, 540
 - see also* HIV
- air quality 47
- Albania
 - GATS commitments 168
 - unofficial health care economy 156
- alcohol use 5, 11, 36
 - by young people 62, 64, 65, 66, 67, 68–9
 - cost-effective analysis 480–86, 488–9
 - legal drinking age 84
 - and traffic deaths 10
 - Zero Tolerance laws 68–9
- Alzheimer Disease 364
- ambulance services, and EuroWill project 396–7, 398
- amphetamines 85
- anthropometric records 48
- antibiotics 173, 540
- Antigua and Barbuda, GATS commitments 168
- antimicrobials 53
- antiretrovirals 54, 58
- Argentina
 - child mortality 50
 - unofficial health care economy 159
- Armenia, GATS commitments 168
- Arrow, K.J. 46, 97–8, 104, 131, 270, 394
- arthritis 114, 115, 118
- Asia, equity in health and health care systems 205–18
 - benefit incidence analysis 209–11
 - empirical analysis of 205–6
 - empirical evidence 206–14
 - Equitap study 206, 208, 209, 210, 211, 212
 - ETEN (equal treatment for equal need) 207
 - Europe, comparisons with 213–14
 - financing, vertical equity in 211–12, 214
 - future agenda 215–16
 - high income countries 207, 209
 - low- and middle-income countries 206–7, 208, 209, 211, 214, 215–16
 - poverty impact of health care expenditure 212–13, 216
 - private financing 214
 - rent-seeking 215
 - social security systems 214
 - tax systems, predominant 214–15
 - transition economies 215
 - see also* individual countries
- Asian Development Bank 254
- assisted living 298
- asthma 77, 120, 367
- Auld, M. Christopher 36–45, 68, 152, 154
- Australia
 - child mortality 50
 - cost-effective analysis 495, 498
 - drug insurance scheme, national 120
 - drug-related crime 83, 85
 - drugs price bargaining 237
 - GATS commitments 168

- health care use 150
- health services trade 170
- patient cost sharing 118–19
- pharmaceuticals evaluation 430, 498, 537, 541–2, 543
- providers, temporary movement of 171, 172
- Austria 23, 24
 - child mortality 49
 - GATS commitments 168
 - hospital competition 228
- back problems 10, 42
- bandwagon effect 62–3
- Bangladesh
 - child health and maternal services 209
 - child mortality 207
 - contracting-out 252, 254
 - government social spending 209
 - health care financing 212
 - health care utilization 208
 - health inequalities 206
 - poverty and health care expenditure 212, 213
 - providers, temporary movement of 171
 - tax and direct payments mixed systems 215
 - unofficial health care economy 156–7, 158
- Barbados, GATS commitments 168
- bargaining in health care *see* negotiation and bargaining in health care
- Barros, Pedro Pita 233–41
- Basu, Anirban 154, 430, 442, 455–65
- Bayesian decision theory 110, 515, 516–17, 531, 540
- behaviour, causal effects of health-related 36–45
 - heterogeneous effects 40–43
 - instrumental variables estimation 36–40
- behaviour, health, and young people 62–71
- Belgium
 - health insurance 112
 - hospital competition 228
 - Panel Study 23, 24
- Belize, GATS commitments 168
- Bernoulli, Daniel 96
- Birch, Stephen 471, 477, 484, 492–502
- Bishai, David 46–61
- Bismark health care systems 223, 228
- Bleichrodt, Han 347–58, 373, 386, 388, 393, 405
- BMI (body mass index) 66, 72–3, 75, 78
- Bolivia
 - GATS commitments 168
 - unofficial health care economy 159
- Boots Pharmaceuticals 307
- Botswana, GATS commitments 168
- Bound, J. 26, 28, 31, 32, 33, 39
- Box-Cox models 440–41, 442–3
- Bradford, W. David 306–14, 339
- 'brain drain' 171–2
- Brazier, John 348, 360, 361, 365, 371–81, 388, 405
- breast cancer 77, 455–6
 - QALY outcome 456, 463–4
- Breyer, Friedrich 126–36
- Briggs, Andrew 480, 488, 503–13, 515, 528
- Brunei Darussalam, GATS commitments 168
- Bulgaria
 - GATS commitments 168
 - unofficial health care economy 156
- Burgess, James F., Jr 320, 335–42
- Burgess, Leonie 386, 405, 406, 408, 415–26
- Burkina Faso, public health intervention 55
- Burundi, GATS commitments 167, 168
- Cambodia
 - contracting-out 252, 254, 256
 - unofficial health care economy 156, 162
- Canada
 - ageing in 31
 - bargaining in health care 237
 - child mortality 50
 - cost-effective analysis 495, 498–9, 537
 - DCA (direct to consumer advertising) 306, 313
 - drug plans for seniors 116
 - drug-related crime 83, 85
 - GATS commitments 167
 - inequalities in self-reported health 181
 - NPHS (National Population Health Survey) 29
 - OHIP (Ontario Health Insurance Plan) 29
 - patient cost sharing 118–19
 - payment rates 265
 - Pharmacare 118, 119, 120
 - pharmaceuticals evaluation 116, 495, 498–9, 537, 541–2
 - providers, temporary movement of 171, 172
 - public drug plan 119–20
 - quality assessment 362–3, 366
 - SLID (Survey of Labour and Income Dynamics) 20
 - taxing health benefits 114–15
 - USA, importing drugs from 114, 121
- cancer 7, 8, 9, 77, 78, 447, 452, 486
 - and EuroWill project 398
 - and QALY model 349
 - screening 290
 - see also* breast cancer; cervical cancer

- capitation system
 contracts, information and incentives in
 health care 263, 264, 265–7
 and decision-making 273
 future research 275–6
 and GPs 269–78
 health services quality and quantity, effects
 on 272–3
 and hospitalization 271, 274
 and mental health 290
 need-based 274–6
 and primary care incentives 269–78
 referral rate 273–4
 revenue system component 274–5
 risk adjustment *see* risk adjustment
- cardiovascular disease 469, 477
 and advertising 310
 cost-effective analysis 483
 and economic instability 5, 7, 8, 9
 EPIC drug 542
- care homes *see* nursing home quality of care
- Caribbean, providers, temporary movement of
 171
- cataract operations, and EuroWill project 398
- cereal breeding programmes 52
- cervical cancer 469
- Chalkley, Martin 224, 234, 242–9, 250, 275,
 323
- children
 in developing countries, public health
 interventions 46–61
 mortality 5, 8–10, 46, 48–51, 53–5, 58, 159,
 205, 206–7, 251, 254
 nutrition, effective 48–51, 486
see also poverty; young people
- Chile
 child mortality 50
 health services trade 170
- China
 cross-border supply of services 167
 GATS commitments 168
 health care financing 212, 215
 health care utilization 208
 legal drinking age 84
 poverty and health care expenditure 212, 213
 smoking 65
 unofficial health care economy 156
- Chinese Taipei, GATS commitments 168
- Chisholm, Dan 479–91
- cholera 54
- cholesterol levels 540–41
- chronic illness 18, 29, 32, 114, 115, 289, 540
 and advertising 310
 health utility measurement 347–52
- Claxton, Karl 480, 488, 514–25, 542
- cocaine 64, 84, 85
- Colombia, unofficial health care economy 159,
 160
- colon cancer 78
- Columbia, child mortality 50
- communicable diseases 48
- community care, and EuroWill project 398
- community support, loss of 12
- CON (certificate of need) policies 298, 300,
 301, 302
- Congo RP, GATS commitments 168
- consumer behaviour, neoclassical model of 62
- Contoyannis, Paul 17–25, 119, 190
- contracting-out health service provision
 250–58
 accountability 257
 contract evaluation 253
 examples of recent 254–6
 external funding 256
 future research 257
 and globalization 257
 government subsidies 251
 impact on health system 257
 international funding agencies 250
 motivation for 251–2
 New Public Management 251
 performance-based 256
 policy implications 256–7
 resource allocation 251–2, 254, 255, 256–7
 in resource- and information-poor settings
 250–58
 services suitable for 252, 255
- contracts, information and incentives in health
 care 242–9
 capitation system *see* capitation system
 costs of health care 245–6
 dumping 245–6
 fee-for-service systems 263, 264, 266, 270,
 271, 272, 275, 286, 290
 fixed prices, policy implications of 246–8
 hidden information 243, 244–6, 250, 256
 moral hazard 243–6, 323
 rent-seeking behaviour 248
 salary system 263–4, 270
 services, defining 247–8, 250
- Cookson, Richard 24, 194, 221–32, 247, 385
- cooperatives 254–5
- Copas' tests 444
- cost-effectiveness acceptability curve (CEAC),
 and decision-making 515–16
- cost-effectiveness analysis and clinical trials,
 statistical methods 503–13
 applications 508–10

- extensions 508–10
- Heart Protection Study 509–10, 511
- ICER statistic 504, 505, 507
- net-benefit regression 506–7, 508
- net-benefit statistic 504–5
- QALY 509
- standard approach to stochastic 503–6
- cost-effectiveness analysis, decision rules for
 - incremental 469–78
 - ‘competing choice’ problem 473–5
 - framework extensions 476–8
 - health improvement, maximising 471–2, 475
 - HIV example 469, 470–71, 475, 476–7
 - indivisibilities 476–7
 - interdependence between programmes 476
 - multiple resource constraints 478
 - programme alternatives 473–5
 - QALY 471–2, 473–5, 495
 - ‘shopping spree’ problem 471–2, 475
- cost-effectiveness analysis, future costs in
 - 447–54
 - empirical studies 449–53
 - ethical and policy concerns 453
 - historical background 447
 - and life expectancy 453
 - lifetime decision-making models 448–9
 - methods 451–2
 - QALY 447, 451, 452
 - theoretical background 447–9
- cost-effectiveness analysis, generalized,
 - principles and practice 479–91
 - alcohol use 480–86, 488–9
 - challenges 479–80
 - IMC-CEA (intervention-mix constrained) 479
 - policy uses 489–90
 - practice of 486–8
 - principles of 480–86
 - QALYs 480, 487, 488, 489, 497, 499
 - risk factors 488–9
 - sectoral analysis 479
- cost-effectiveness thresholds, and decision-making 543–4
- cost-utility analysis *see* health utility measurement
- Costa Rica
 - child mortality 51
 - contracting-out 254–5, 256
 - cooperatives in 254–5
 - GATS commitments 168
 - Social Security Fund 255
- costs for economic evaluation, estimating
 - 429–38
 - censoring 432–5
 - cost analysis 430–35
 - cost collection 429–30
 - generalised equations 435
 - missing data 431–2, 435
 - skewed costs 430–31
- costs and expenditures, skewed data on
 - 439–46
 - alternative estimation approaches 440–43
 - Box-Cox models 440–41, 442–3
 - generalised linear model (GLM) 441–3, 444
 - OLS model 439, 441, 442, 444
 - retransformation problem 441
 - strengths and weaknesses 443–4
- crime and illicit drug use 83–92
- Croatia
 - capitation system for GPs 271
 - GATS commitments 168
- crop breeding programmes 52
- Cuba, health services trade 170
- Currie, Gillian 247, 386, 405–14
- Cutler, D.M. 48, 52, 76, 77, 80, 105, 110, 142, 238, 280, 283, 297, 301
- Cyprus, hospital competition 228
- cystic fibrosis screening 404
- Czech Republic
 - GATS commitments 168
 - health plan competition 221
- Dawson, Diane 221–32, 247
- DCA (direct to consumer advertising) *see* advertising
- Deb, Partha 147–55
- decision rules in economic evaluation 492–502
 - alternative approach 499–500
 - and cost-effective analysis 492–3, 494–500
 - economic basis 492–4
 - needs of decision-makers 495–8
- decision-making
 - CEAC (cost-effectiveness acceptability curve) 515–16
 - central level 537–8
 - clinical studies 539–41
 - cost-effectiveness thresholds 543–4
 - economic evaluation and 537–45
 - evidence acquisition 517–23
 - EVPI (expected value of perfect information) 517–23
 - local level 538–9
 - methodological issues 539–41
 - QALY 541, 543–4
 - requirements of 514–15
 - technology adoption 515–17
 - with uncertainty 514–25
- Dengue fever 54

- Denmark
 capitation system for GPs 271
 child mortality 49
 EuroWill project 398
 hospital competition 228
 Panel Study 23, 24
 physician payments 266
 public health expenditure 221
 willingness to pay 398, 399
- dental care 132
- depression 115, 289
 Robert Wood Johnson Foundation 289
- developing countries
 child mortality 46
 e-health 169
 FDI 170–71
 health care workers, shortage of 52–3, 58
 and health services trade 170
 public health interventions for children in
 46–61
 water quality 52
see also individual countries
- diabetes 120, 283, 289, 290, 309, 450, 452, 540
 type 2 77, 78
- dialysis 364, 452
- diarrhoea 52, 183, 209
- diet 10, 12, 18, 73, 452
 calorie consumption 73–4
 food as addiction 76
 food price 52, 66, 75–6, 77, 79
see also nutrition; obesity
- digestive system 200
- disability insurance 26, 29, 31, 32, 33
- Discrete Choice Experiment 386
- Dolan, Paul 129, 352, 355, 361, 373–4, 376,
 382–91, 384, 385, 387, 541
- Dominican Republic, GATS commitments 168
- Donaldson, Cam 247, 270, 372, 392–402, 405,
 411, 497, 499, 544
- donor agencies 52
- Dowd, Bryan 99, 111, 137–46, 221, 247
- DPT vaccine 54
- Dranove, D. 39, 224, 226, 265, 331, 429, 430
- DRGs (Diagnosis Related Groups) 224, 225,
 228, 229
- drug use 36, 40, 62–6, 67, 68
 amphetamines 85
 background on illicit 83–4
 cocaine 64, 84, 85
 crime and illicit drug use 83–92
 decriminalization 87, 88–9
 demand and supply 86–8
 dependency 84
 and employment 84
 future research challenges 89–90
 harm-reduction 88–9
 heroin 84, 87
 inhalant drugs 84
 legalities of 83, 84
 legalization 87, 88–9
 ‘lifestyle’ drugs 118
 marijuana 66, 67, 83, 84, 88
 needle exchange 88–9
 PA (prior authorization) for prescription
 drugs 118
 patient cost sharing 118–20
 prescription drug insurance, moral hazard
 116–21
 prescription drug insurance and
 reimbursement 114–25
 prescription drug price discounts 120–21
 preventive programmes 87–8
 and sexual behaviour 40
 smuggling 88
 treatment for 85, 87
see also individual countries
- Drummond, Michael 56, 359, 365, 371, 430,
 479, 500, 505, 537–45
- dual practice 157
- dynamics of health 17–25, 30, 33
 empirical analysis of 19–21
- dyslipidemia 77
- ear complaints 200
- Eastern Europe
 providers, temporary movement of 171
see also individual countries
- ECHP (Economic Community Panel) 21
- ECHP-UDB (*European Community Household
 Panel User Database*) 23
- economic evaluation, distributional
 judgements in 382–91
 ability to pay 383
 Discrete Choice Experiment 386
 efficiency counter-argument 383
 health variance 385–6
 horizontal equity 384, 386
 QALY, equality of 382–90
 QALY, maximization, weighted 388–90
 QALY, value of 386–8, 393, 394, 397–9
 social perspective 386–7
 vertical equity 383–4, 385
see also preference-based measures for
 health; quality of life assessment, health-
 related
- economic growth
 and child mortality 51
 and health decline 11–12

- Ecuador, GATS commitments 168
 education levels 17, 18, 19, 199, 202, 203
 education and training 167, 170
 emphysema 534
 employment
 and health insurance 108
 and health service utilization 202, 203
 and illicit drug use 84
 injury risk at work 11
 labour supply 30, 31, 32, 33
 sedentary 75
 working hours 11
 see also health, and work; workforce
 endocrine and metabolic disorders 200
 endometrial cancer 78
 England
 equity in health care consumption 199–203
 see also UK
 Ensor, Tim 156–63, 215
 environment, physical 7, 18, 46, 47
 epidemiologic surveillance 47
 epilepsy 540
 Equitap study 206, 208, 209, 210, 211, 212
 equity in consumption of health care
 economic studies of 193–204
 in England 199–203
 horizontal and vertical inequity, recognising
 198–9
 inequity, problems in analyses of 196–9
 welfare maximization and need 193–6
 equity in health and health care systems, Asia
 see Asia
 Estonia
 capitation system for GPs 271
 GATS commitments 168
 Ettner, Susan L. 266, 276, 286–95
 EU
 DCA (direct to consumer advertising) 306,
 313
 Equitap study 206
 GATS commitments 168
 health insurance and international
 purchasing 134
 macroeconomic effects on mortality 7, 8
 Europe
 Asia, comparisons with, equity in health and
 health care systems 213–14
 Bismark health care systems 223, 228
 child mortality 46
 comparisons with, Asia, equity in health and
 health care systems 213–14
 dual practice 157
 GP and specialist use 208
 health care financing 211
 health insurance 147
 health plans 138
 incentive reimbursement 266
 inequalities in self-reported health 181, 183
 retirement 27
 see also individual countries
 EuroQol EQ-5D measure 361–2, 364, 365, 366,
 372, 373, 377
 EuroWill project 396–7, 398
 Evans, David B. 479–91
 exercise 10, 12, 36, 73, 75, 79, 452
 physical inactivity 10, 11
 see also diet; obesity; weight
 eye complaints 200, 308–9, 373

 family planning 52, 53
 fee-for-service systems 263, 264, 266, 270, 271,
 272, 275, 286, 290
 Feeny, David 359–70, 371, 372, 375, 388, 405
 Feldman, Roger 99, 111, 137–46, 221, 247
 Fenwick, Elisabeth 480, 488, 514–25, 531, 542
 Fieller's theorem 504
 finite-sample properties, literature on 38–9,
 40
 Finland
 child mortality 49
 GATS commitments 168
 hospital competition 221
 obesity 10
 Panel Study 23, 24
 food pricing policies 52, 66, 75–6, 77, 79
 foreign travel 170, 173
 see also migration
 France
 child mortality 49
 drug prescription 118
 EuroWill project 398
 hospital competition 228, 229
 legal drinking age 84
 Panel Study 23, 24

 Gafni, Amiram 262, 393, 397, 471, 477, 486,
 492–502, 544
 gallbladder disease 77, 78
 Gambia
 child mortality 58
 GATS commitments 167, 168
 public health intervention 54, 58
 Gamma model 444
 GATS (General Agreement in Trade in
 Services) 165–7, 168, 171, 172, 173
 generic products 307
 genitourinary system 200
 genomics 173

- Geoffard, Pierre-Yves 58, 104–13, 116, 131, 280
- Georgia, GATS commitments 168
- Gerard, Karen 247, 270, 386, 393, 405–14
- Gerdtham, U.-G. 5, 6, 7, 9, 10, 11, 119, 128, 149, 154, 181
- Germany
 child mortality 49
 health plans 145, 285
 hospital competition 228, 229
 income levels 11, 19
 macroeconomic effects on mortality 7, 8, 10, 11
 outpatient visits 149
 Panel Study 23, 24
 pharmaceutical expenditure 271
 social health insurance 128, 130
 Socioeconomic Panel (GSOEP) 19
 unemployment 32
- Gertler, P.J. 299, 300, 301, 337, 338
- GHQ (General Health Questionnaire) 23, 199
- Gini indices 22, 187
- Glazer, Jacob 112, 132, 235, 275, 279–85
- globalization
 consumption abroad 169–70
 and contracting-out health service provision 257
 cross-border supply of services 167–9
 e-health 167, 169
 education and training, web-based 167
 FDI (foreign direct investment) 170–71
 future prospects 172–3
 GATS 165–7, 171, 172, 173
 and health economics 173–4
 health governance, global 172
 providers, temporary movement of 171–2
 and trade in health services 164–75
 and waiting lists 173
- Gold, M. 102, 374, 429, 430, 447, 493
- gonorrhoea 69
- government policies 46, 47, 64–5
 and hospital competition 228–9
 subsidies 251
see also individual countries
- GP (general practitioner) fundholding (UK) 117–18, 119, 227, 238, 271, 274
- Grabowski, David C. 266, 296–305
- Gravelle, Hugh 5, 181, 193–204, 227, 272, 274, 275
- Greece 23, 24
- Grootendorst, Paul 40, 114–25, 365
- Grossman, Michael 11, 12, 17–18, 20, 27, 46–7, 62, 63–4, 66, 79
- Guyana, GATS commitments 168
- haemophilus influenza B 58
- Haiti, contracting-out 256
- hallucinogens 84
- Handbook of Health Economics* 296
- Harvard death spiral 110
- hay fever 307
- health
 demand for 17–18
 inequality 21–2
 limitations 23–4
 persistence in 18–19
 predisposition to poor 18
 and work, empirical models for 30–32
 and work, literature on 28–33
 and work, model for 26–8
 and work, structural models for 32–3
- health capital model 11
- health care, contingent valuation in 392–404
 ability to pay 394
 clinical dilemmas 394–6
 decision maker's dilemmas 394–9
 health dilemmas 396–7
 national dilemmas 397–9
 WTP (willingness to pay) 392–9
- health care, contracts, information and
 incentives in *see* contracts, information
 and incentives in health care
- health care economy, unofficial
 additional services enhancements 158
 and child mortality 159
 consumer choice of quality 161
 contracting approaches 160–61
 corruption approaches to 159–60, 161, 162
 drugs payments 156
 dual practice 157, 160–61, 162
 'inxit' theory 158
 in low- and middle-income countries 156–63
 modelling 159–61
 policy implications 161–2
 'Robin Hood' effect 158
 and wage levels 160, 161
 willingness to pay 158
- health care, equity in consumption of *see*
 equity in consumption of health care
- health care evaluation, perspectives on mean-based 526–36
 CEAC (cost-effectiveness acceptability curves) 533–4
 CER (cost-effectiveness ratios, incremental) 533–4
 current criteria 533–5
 decision-making 526–33
 monetary benefit measures (NHBs) 533–4
 net health benefit measures (NHBs) 533–4

- quantile treatment effects 534–5
- risk factors 527–33
- welfare assessment 534
- health care, inequalities in *see* inequalities in health care
- health care, negotiation and bargaining in health care *see* negotiation and bargaining in health care
- health care organizations, performance measurement *see* performance of health care organizations
- health care professionals, motivation of 248–9
- health care, publicly funded, hospital competition and patient choice *see* hospital competition and patient choice
- health care systems, use of performance measures in *see* performance measures in health care systems
- health care use
 - empirical models of 147–55
 - endogenous covariates 151–3
 - equity in 207–9
 - exogenous covariates 148–51
 - hurdle or two-part models 148–9, 150, 151
 - latent class models 150–51
 - parameters 153–4
 - Poisson regression model 148, 149, 150, 442, 444
 - zero-inflated models 149–50
- health economics, choice experiment design 415–26
 - binary response experiments 419
 - choice models 417–19
 - discrete choice experiments 415–21
 - generic choice experiments 419–23
 - random utility theory 417–19
 - resolution 3 design 419
 - Scale Decomposition Model 425
 - understanding choice behaviour 416–17
 - unresolved issues 424–5
- health economics, discrete choice experiments in 405–21
 - attribute identification 406–7
 - choice sets construction 407–8
 - concept of 406
 - data analysis 408–10
 - feasibility of 417
 - price as an attribute 407
 - QALY model 405, 410, 411
 - stages of 406–10
 - survey design 408
 - time as an attribute 407
 - validity of 411–12
 - willingness to pay 406, 410
- health insurance 26, 27, 29, 79
 - adverse selection 115–16, 126, 147
 - certainty, demand for 96–8, 105, 111
 - demand, price elasticity 108, 109
 - and e-health 169
 - employment linked 108
 - and FDI 170
 - and financial liberalisation 165
 - first best 105–6
 - health plans *see* health plans
 - incentive and selection effects in 104–13
 - income transfers, demand for 100–102, 105
 - ‘industrial purchasing’ 144
 - managed competition 144
 - market, and health plans 144–5
 - moral hazard 95, 98–9, 100, 101, 102, 104, 105–7, 108, 116–21
 - and mortality 111
 - physician as patient’s agent *see* physician as patient’s agent
 - pre-payment schemes 117–18
 - prescription drug 114–25
 - private, characteristics of 126–7, 137
 - RAND Health Insurance Experiment (HIE) 99, 109–10, 131, 151, 286, 440
 - reference pricing schemes 119, 120
 - regulation of 108
 - reimbursement 106–7
 - risk prediction 115–16, 126, 127, 142
 - second best 106–8
 - social *see* social health insurance
 - solidarity in 127–8
 - taxation, optimal 126–7
 - technological change in medicine 134
 - tiered cost sharing 119
 - USA *see* USA
 - utility concept 96, 97, 98, 101, 105
 - value of 95–103
 - welfare gain 100, 101, 102, 114, 142
 - welfare loss 98–9, 100, 101, 104–5, 121
- health plans
 - basic choice model, variations on 141–3, 152
 - choice literature 137–8, 142
 - competition and choice 137–46, 147, 221, 247
 - consumer characteristics 142
 - and health insurance market 144–5
 - individual level data 138–40
 - and market for health care services 143–4
 - market share data 140–41, 142
 - mental health patients 286–7
 - mergers 138
 - physician loyalty 137
 - plan switching 142–3

- profit maximization 283–4
 quality choices 282–4, 288, 330
 and risk adjustment *see* risk adjustment
 risk segmentation 142
 service-level selection 282–3
 study methods 138–41
 value-based purchasing 288
- health services trade and globalization *see*
 globalization
- health utility measurement 347–58
 characterizations under expected utility
 348–9, 353–4
 chronic health states 347–52
 generic utility model 351
 life duration trade off 351–2
 non-chronic health states 352–5
 non-expected characterizations 350, 351, 355
 prospect theory 351
 QALY (quality-adjusted life-year) model
 347, 348–50, 351, 353–4, 355–6, 366, 367,
 371, 372
 zero condition 348–9, 350
- health-related behaviour, causal effects of *see*
 behaviour
- heart disease 7, 8, 9, 10, 77, 120, 200, 289, 447,
 450
 and EuroWill project 398
 myocardial infarction 7, 226
 and performance monitoring 330, 331–2
 risk reduction 392
 treatment decision rules 493
- Heart Protection Study 509–10, 511
- Heckman, J.J. 41, 42, 108, 457, 462, 526, 533,
 535
- helicopter ambulance 396–7, 398
- Hepatitis B 54
- Herfindahl-Hirschman Index of concentration
 226
- heroin 84, 87
- Hicks, J.R. 52, 338, 395
see also Kaldor-Hicks theory
- hip
 fracture prevention 452
 operations, and EuroWill project 398
 treatment decision rules for 493
- HIV 58, 251, 252, 452, 469, 470–71, 475,
 476–7, 479, 540
 QALY 470
- Holland *see* Netherlands
- home health care 298
- homicide 62
 and economic instability 5, 7–10
- Hong Kong
 government social spending 209, 211
- health care financing 211, 212, 214
 health care use 207
 health care utilization 208
 poverty and health care expenditure 213
 tax systems, predominant 214–15
- hormone replacement therapy 452
- hospice care 298
- hospital competition and patient choice
 221–32
 Bismark health care systems 223, 228
 corporatism 228, 229
 cross-border patient movement 228
 DRGs (Diagnosis Related Groups) 224, 225,
 228, 229
 economic theory of 222–6
 economies of scale 224
 emergency services 224
 entry and exit regulations 224, 225
 fixed price regulation and non-price
 competition 225
 geographical equity of access 226
 imperfect, with no price regulation 224–5
 ‘league table’ competition 223
 ‘medical arms race’ 223
 monopolistic 224–5
 political constraints 228–9
 price regulation 223–4
 public funding limits 224, 225, 228–9
 in publicly funded systems, evidence on
 226–8
 quality and waiting times 225, 227, 238
 regulatory environment 223–4
 reimbursement 223, 228
 rent-seeking 228, 229
 ‘selective contracting’ 224
 supply-side impediments 223, 224
 worker satisfaction 229
- hospitals, productivity measurement 336, 337
- HUI (Health Utilities Index) 361, 362, 363–4,
 365, 366, 372, 373
- Hungary
 GATS commitments 168
 unofficial health care economy 156, 158
- hygiene 48–51, 486
- hyperlipidemia 115
- hypertension 77–8, 115, 118, 119, 120, 447,
 452, 477, 486
 willingness to pay 403
- IMCI (Integrated Management of Childhood
 Illness) 53
- immunization 53, 54, 55, 57–8, 254
 and performance-based bonuses 290
see also vaccination

- incentives in health care *see* contracts,
information and incentives in health care
- income levels 6, 10–11, 17, 18–19, 20, 21–3,
28
and distributional judgements 383, 384
and health service utilization 202, 203
income mobility 21–4
and weight 75
- India
child health and maternal services 209
child mortality 51, 207
contracting-out 252
e-health 169
FDI 170
GATS commitments 168
government social spending 209, 211
health care financing 212, 214
health inequalities 206
health services trade 170
poverty and health care expenditure 213
providers, temporary movement of 171
tax and direct payments mixed systems 215
- Indonesia
child health and maternal services 209
child mortality 51, 207
government social spending 209
health care financing 212, 214
health care utilization 208
poverty and health care expenditure 212, 213
tax and direct payments mixed systems 215
- inequalities in health care
concentration index via linear regression
179–83
decomposition of 179–92
difference in means 183–6
distribution changes 186–90
Oaxaca-type decomposition 179, 180–81,
182, 183, 184, 187
- infants *see* children
- infectious diseases 199, 200
- infertility services 410
- influenza 7, 8, 9, 58, 452
OTA study 447
- insecticide treated nets 53, 55
- international funding agencies 250
- 'inxit' theory 158
- Ireland
EuroWill project 398
Panel Study 23, 24
- Islamic societies, child mortality 51
- Israel, health plans 221, 285
- Italy
child mortality 49
hospital competition 221
Panel Study 23, 24
prescribing behaviour 309
- Iversen, Tor 117, 265, 266, 269–78
- Jamaica, GATS commitments 168
- Japan
child mortality 50
equity in health care 205
GATS commitments 167, 168
health care financing 211, 212, 214
health care use 207
social security systems 214
- JCAHO (Joint Commission on Accreditation
of Health Care Organizations) 288, 290,
292
- Johannesson, M. 5, 6, 119, 350, 355, 393, 394,
397, 399, 430, 450, 495, 541
- Jones, Andrew M. 17–25, 65, 108, 190, 198,
444
- Jordan, GATS commitments 168
- Kakwani indices 158
- Kaldor-Hicks theory 395, 526, 527, 529–31,
534
- Kazakhstan, unofficial health care economy
158, 161
- Kenkel, Don 62–71, 154, 312
- Kleit, Andrew N. 306–14
- Korea
health care financing 211, 214
health care use 207
poverty and health care expenditure 213
social security systems 214
- Kuwait
child mortality 51
GATS commitments 168
health care quality 170
- Kyrgyzstan
GATS commitments 168
government social spending 209
health care financing 212, 214
social security systems 214
unofficial health care economy 156, 161–2
- labour supply 30, 31, 32, 33
see also employment
- Lagrange multiplier 195
- Lakdawalla, Darius 64, 72–82, 297–8
- Latin America
unofficial health care economy 156, 159, 161
see also individual countries
- Latvia, GATS commitments 168
- league tables, mortality 329
- Leapfrog Group for Patient Safety 288

- leisure time 12, 27, 32–3
- Lesotho
 contracting-out 252
 GATS commitments 168
- Lindeboom, Maarten 19, 21, 26–35
- Lithuania, GATS commitments 168
- liver disease 7, 8, 9
- location-specific fixed effects, and pooled data 6–11
- Louvière, Jordan 143, 386, 405, 406, 415–26
- Lurås, Hilde 117, 265, 266, 269–78
- Luxembourg
 hospital competition 228
 Panel Study 23, 24
- Macao, cross-border supply of services 167
- Macedonia, GATS commitments 168
- McFadden, D. 138, 377, 406, 408, 417, 418, 424
- McGuire, Ali 247, 429–38
- McGuire, Thomas G. 112, 132, 235, 242, 270, 275, 279–85, 323
- macroeconomic conditions
 and health and mortality 5–12
 location-specific fixed effects 6–11
- Madagascar, contracting-out 252
- malaria 47, 52, 54, 55, 251, 479, 486
- Malawi
 contracting-out 252
 GATS commitments 168
- Malaysia
 equity in health care 205
 FDI 170
 GATS commitments 168
 government social spending 209, 211
 health care utilization 208
 tax systems, predominant 214–15
- mammography, and performance measurement 332
- Manning, Willard 99, 102, 109, 128, 131, 149, 247, 430, 431, 439–46, 504, 508
- marijuana 66, 67, 83, 84, 88
- Martinez-Giralt, Xavier 233–41
- Mason, Helen 247, 392–402, 405
- measles 48, 54, 57
- Medicaid 95, 101, 118, 537
 and advertising, direct to consumer 312–13
 drug programme 120–21
 financial incentives 288–9
 mean-based evaluation 527
 nursing home quality of care 296, 297, 298, 299, 300–301, 302
 and obesity 78, 79
 payment system 246
 prescription reimbursement 119
 report card 330
 risk adjustment 284
- medical care, and health insurance *see* health insurance
- medical research 173
- Medicare 95, 137, 223, 287, 455–6, 463
 and advertising, direct to consumer 313
 financial incentives 288–9
 hospital care 117, 226, 248
 nursing home quality of care 296, 297, 298, 299, 301–2
 and obesity 78, 79
 open enrolment 246, 248, 265, 281, 282
 payment system 142, 225, 246, 248, 265
 risk adjustment 284–5, 440
- Medline 167
- Meltzer, David 399, 447–54, 488
- meningitis 54
- mental health 200, 486
 and economic instability 5, 10, 11, 12
 financial incentives 288–93
 and illicit drug use 84
 incentives in improving care quality 286–95
 inequalities in 19, 23
 patients' abilities, undermining 286
 pay-for-performance programmes 288, 289–90
 psychosocial health 199
 quality measures, evaluation of 290–93
 risk adjustment 292
 value-based purchasing 288
- methadone maintenance 87
- Mexico
 child mortality 50
 GATS commitments 168
 and health services trade 170
- migration 12, 170, 171, 172
see also tourism
- Mills, Anne 55, 212, 250–58
- Miyamoto, J.M. 348–9, 350, 351, 352
- mobility indices 21–4
- Moldova, GATS commitments 168
- Mongolia, social security systems 214
- Monte Carlo model 40, 56, 515, 540
- Mooney, G. 197, 262, 266, 270, 271, 392, 393
- morphine 84
- Morris, Stephen 193–204
- mortality
 adult 7–10, 297–8
 child 5, 8–10, 46, 48–51, 53–5, 58, 159, 205–7, 251, 254
 decline, and public health intervention 48–51
 elderly 297–8

- and health care inequity 196–9
- and health insurance 111
- and hospital competition 226–7
- league tables 329
- and macroeconomic conditions 5–12
- and performance measurement 323, 329, 330–31
- reduction, and vitamin A supplementation 48, 55, 57, 58
- Mozambique, public health intervention 54
- Mullahy, John 152, 154, 430, 441, 442, 444, 504, 514, 515, 526–36
- musculoskeletal system 199, 200
- negotiation and bargaining in health care 233–41
 - ‘any willing provider’ approach 235, 236, 239
 - future research 239
 - group preferences 237
 - models of 234–7
 - Nash bargaining solution 234–5, 237
 - outcomes evidence 237–8
 - pharmaceutical product financing 237, 239
 - public-private partnerships 236–7, 239
 - third-party payer decisions 235–6, 237, 238, 239
 - timing of 239
- neonatal deaths, and economic instability 8
- neoplasms and benign growths 200
- Nepal
 - child health and maternal services 209
 - child mortality 51, 58, 207
 - FDI 170
 - health care financing 212, 214
 - health care utilization 208
 - health care workers, shortage of 53
 - health inequalities 206
 - poverty and health care expenditure 213
 - public health intervention 55, 58
 - tax and direct payments mixed systems 215
 - unofficial health care economy 156
 - vitamin A programme 58
- nervous system 200
- Netherlands
 - capitation system for GPs 271
 - health expenditure 129
 - health plan competition 221
 - health plans 145, 285
 - hospital competition 228
 - marijuana use 83
 - Panel Study 23, 24
 - pharmaceuticals evaluation 542
 - social health insurance 130
- New Zealand
 - DCA (direct to consumer advertising) 306
 - hospital competition 221
 - providers, temporary movement of 171
- Newhouse, J.P. 109, 126, 128, 221, 223, 247, 270–71, 283, 338, 339, 340
- Nigeria
 - contracting-out 252
 - public health intervention 55
- NLSY (National Longitudinal Survey of Youth) 67, 68, 75
- NOAA (National Oceanic and Atmospheric Administration) 394
- Norton, Edward C. 266, 296–305
- Norway
 - capitation system 274
 - child mortality 49
 - EuroWill project 398
 - GATS commitments 168
 - helicopter ambulance evaluation 396–7, 398
 - hospital competition 228
 - providers, temporary movement of 172
 - public health expenditure 221
 - social insurance reform 42
- nursing home quality of care 296–305
 - chain ownership 298
 - CON (certificate of need) policies 298, 300, 301, 302
 - demand-side 297–8
 - literature review 300–303
 - market characteristics 297–300, 302
 - Medicaid payments 296, 297, 298, 299, 300–301, 302
 - Medicare payment 296, 297, 298, 299, 301–2
 - occupancy rates 298, 300
 - OSCAR reporting systems 299
 - ownership type 302–3
 - productivity measurement 336, 337, 340
 - publicizing 303
 - quality assurance 299–300
 - service financing 296–7
 - supply-side 298
- nutrition 48–51, 52, 55
 - food fortification 52
 - vitamin A *see* vitamin A
 - see also* diet
- Nyman, John A. 95–103, 104, 107, 117, 128, 299, 300, 301, 451
- Oaxaca-type decomposition 179, 180–81, 182, 183, 184, 187
- obesity 10, 11, 12
 - behavioural theory of weight 76–7, 80
 - consequences of 77–9

- economics of 72–82
- food addiction 76, 77
- health implications 77–8
- labour market effects 78–9
- and Medicaid 78, 79
- neoclassical case for intervention 79–80
- neoclassical theory of weight 74–6, 77
- over-eating 36
- and public policy 79–80
- and snack food 77
- Swedish Obese Subjects (SOS) study 78
- trends in 72–4
- in young people 62, 66
- see also* diet; weight
- O'Brien, B. 365, 372, 394, 397, 430, 498, 504, 527, 534
- obstetrics
 - and performance measurement 332
 - see also* pregnancy
- O'Donnell, Owen 179–92, 193, 209, 211
- OECD
 - health care financing 211
 - macroeconomic effects on mortality 8, 9, 10
 - public health expenditure 221, 222
 - see also* individual countries
- Olmstead Decision, Supreme Court 298
- Olmstead, Todd A. 83–92
- OLS model 439, 441, 442, 444
- Olsen, J.A. 129, 383, 384, 386, 392, 394, 396, 397, 429
- Oman, GATS commitments 168
- ophthalmology 200, 308–9, 373
- organ transplants 132
- OSCAR reporting systems 299
- osteoarthritis 77, 312, 366
- osteoporosis 452
- Pakistan
 - child health and maternal services 209
 - child mortality 51, 58, 207
 - contracting-out 252
 - GATS commitments 168
- Palmer, Natasha 250–58
- Panama, GATS commitments 168
- patient preferences 411
- Pauly, M. 98, 99, 104, 115, 116, 126, 144, 238, 339
- 'pay-for-performance' schemes 266, 267, 276, 288, 289–90
- penicillin 48
- pension plans 26–7
- performance of health care organizations,
 - measuring 317–25
 - adverse selection 321–3, 324
 - agent generated 321–3
 - conjoint analysis 320
 - gaming 322–3, 330
 - joint outputs 324
 - measurement instruments 321–3
 - moral hazard 323–4
 - mortality rates 323
 - parametric frontier methods 320
 - patient satisfaction 321
 - principal-agent model 317–18, 321, 323–4, 326–7
 - principal's objectives 319–20
 - 'ratchet' effect 322–3
 - targets and rewards 321–2
 - waiting times 323
- performance measures in health care systems,
 - use of 319, 326–34
 - behavioural impact 330–31
 - 'best practice' 327
 - evidence on use and impact of 329–32
 - gross outcomes 327–8
 - motivation, intrinsic 326–7
 - net outputs 328
 - not-for-profit organizations 326
 - outcome impact 331–2
 - PCPA (physician clinical performance assessment) 329
 - process and outcome measures 327–8
 - public disclosure 328, 330
 - rationale for 327–9
 - special features 326–7
- performance-based bonuses, and immunization 290
- personal medical care 46–7
- personal responsibility 384, 385–6
- see also* self-assessed health
- pertussis 57
- Peru, unofficial health care economy 159
- Pharmacare 118, 119, 120
- pharmaceuticals
 - advertising *see* advertising
 - evaluation *see* individual countries
- Philippines
 - child health and maternal services 209
 - child mortality 51, 58, 207
 - health care financing 212
 - poverty and health care expenditure 213
 - providers, temporary movement of 171, 172
 - public health intervention 55, 58
 - vitamin A programme 58
- Philipson, Tomas J. 58, 64, 72–82, 297–8
- physical inactivity 10, 11
- see also* exercise

- physician as patient's agent 261–8, 270, 286
 agency theory 261–3
 compensation systems 262–4
 DCA impact 309
 economic behaviour 264–7
 economic theories 261–4
 implications 267
 'pay-for-performance' schemes 266, 267, 276, 288, 289–90
 welfare implications 262
- physicians, productivity measurement 336
- Pinto, Jose Luis 347–58, 385, 388, 405
- pneumonia 7, 54, 58, 452
- Poisson regression model 148, 149, 150, 442, 444
- Poland
 GATS commitments 168
 trade in health services 170
 unofficial health care economy 156
- polio 57
- pollution 11
- Polsky, Daniel 154, 430, 455–65, 504
- pooled data, and location-specific fixed effects 6–11
- Portugal
 child mortality 49
 EuroWill project 398
 Panel Study 23, 24
 public-private partnerships 239
- poverty
 and globalization 173
 and health care expenditure in Asia 212–13, 216
 and prescription drug insurance 119
 reduction 51, 88, 173, 251
- preference-based measures for health 371–81
 data preparation 374–5
 health state classifications 371–5
 item generation and selection 372–3
 ME (magnitude estimation) 373
 modelling 375–7
 patient values, use of 374
 PTO (person trade-off) 373, 386
 respondents 374
 SG (standard gamble) 373, 375, 376, 411
 specificity 372
 TTO (time trade-off) 373, 411
 valuation technique 373–4
 VAS (visual analogue scaling) 373
see also economic evaluation, distributional judgements; quality of life assessment, health-related
- pregnancy
 Caesarean section rates 290
 neonatal deaths 8
 obstetrics, and performance measurement 332
 unwanted 62
- prescription glasses 308–9
- price elasticity of derived demands 63
- primary care incentives, and capitation system 269–78
- productivity analysis in health care 320, 335–42
 DEA (Data Envelopment Analysis) 339, 340
 duality theory 335
 economies of scale and scope 336, 337
 efficiency based methods 336–8
 FDH (Free Disposal Hull) 339–40
 and financial incentives 338
 health organizations 337
 inefficiency measurement 338–40
 integrated frontier methods 340
 non-parametric frontier methods 339–40
 nursing homes 336, 337
 parametric frontier methods 339
 patient panel sizes 337–8
 physicians 337–8
 process improvement 340
 RVUs (relative value units) 337
 technical efficiency 336
- Propper, Carol 227, 238, 248, 292, 317, 319, 324, 326–34, 335
- PSID (US Panel on Income Dynamics) 19
- psychosocial health 199
- public health interventions
 children in developing countries 46–61
 community based 52
 cost-effective 56–8
 disease control 52–6
 immunization 53, 54, 55, 57–8
 margins in 47–8
 market failures 47
 and mortality decline 48–51
 and obesity 79–80
 personal intervention 53–6
 technology assessment 56–8
 vs. individual 46–7
- Punjab, child mortality 51
- QALY (quality-adjusted life-year) model
 breast cancer 456, 463–4
 cancer 349
 cost-effectiveness analysis and clinical trials 509
 cost-effectiveness analysis, decision rules 471–2, 473–5, 495

- cost-effectiveness analysis, principles and practice 480, 487, 488, 489, 497, 499
 decision-making 541, 543–4
 economic evaluation, distributional judgements in 382–90, 393, 394, 397–9
 health economics, discrete choice experiments in 405, 410, 411
 health utility measurement 347, 348–50, 351, 353–4, 355–6, 366, 367, 371, 372
 HIV 470
 and testicular cancer 349
 Qatar, GATS commitments 168
 quality of life assessment, health-related 247, 359–70
 applications 365–6
 construct validity 364
 EuroQol EQ-5D measure 361–2, 364, 365, 366, 372, 373, 377
 future directions 366–8
 HUI (Health Utilities Index) 361, 362, 363–4, 365, 366, 372, 373
 and life expectancy 366–7
 multi-attribute utility 359–64, 367, 374
 psychometric measures 359
 Quality of Well Being scale 361, 362, 363, 364
 SF-6D scale 361, 362, 364, 365, 371, 373, 377
 SG (standard gamble) 360, 373
 Short-Form 36 359, 361, 364, 366, 373
 TTO (time trade-off) 360
 VAS (visual analogue scale) 360, 362, 363, 373
 see also economic evaluation, distributional judgements; preference-based measures for health
- Raikou, Maria 247, 429–38, 504
 RAND Health Insurance Experiment (HIE) 99, 109–10, 131, 151, 286, 440
 Rannan-Eliya, Ravindra 193, 205–18
 Rasch analysis 373
 rational addiction model 62, 64
 renal disease 289, 364, 452
 respiratory disorders 52, 77, 200, 209
 retirement 26, 28, 30, 31, 32, 202, 203
 early 18, 27, 31
 see also ageing
 rheumatoid arthritis 114
 rhinitis 367
 Rice, Nigel 17–25, 190, 275
 Rice, Thomas 46, 104, 261–8, 270, 286
 risk adjustment
 adverse selection 281–2, 283
 and ageing 279, 280, 282
 conventional 279, 282, 283
 cost-effectiveness analysis 488–9
 group access 281–2, 284
 health care evaluation 527–33
 health insurance 115–16, 126, 127, 142
 heart disease 392
 individual access 280–81
 mental health 292
 optimal 275–6, 279–85
 practice of 284–5
 quality of care 282–4
 social health insurance 126, 127, 129, 130, 131, 132, 134
 transport safety 392
 see also health plans
 risk factors 486
 Robert Wood Johnson Foundation 289
 Roberts, Jennifer 258, 348, 360, 371–81, 388, 405
 Robinson, James 142, 223, 226, 266, 272, 275, 289
 Romania, trade in health services 170
 rotavirus 54, 58
 ‘rotten kids’ model 64
 Rubin, D. 41, 431, 432, 435, 456, 459
 Rufen ibuprofen 307
 Ruhm, Christopher J. 5–16, 67, 68
 Russia
 health plan competition 221
 performance measurement (former Soviet Union) 322
 smoking 65
 Rwanda, GATS commitments 168
 Ryan, Mandy 247, 262, 320, 386, 393, 394, 395, 397, 405–14, 415, 416
- Saint Lucia, GATS commitments 168
 St. Vincent, GATS commitments 168
 sanitation 47, 55, 486
 SARS virus 173
 Saudi Arabia, health care quality 170
 Scandinavia
 hospital choice 223
 see also individual countries
 schizophrenia 119
 Schoenbaum, Michael 266, 276, 286–95
 screening programmes 46, 410, 412
 Sculpher, Mark J. 410, 429, 480, 488, 498, 504, 514–25, 524, 527, 534, 542
 selection bias in observational data 455–65
 addressing 458–63
 ATE (Average Treatment Effect) 457–8, 460–61, 462, 463

- breast cancer example 455–6, 463–4
- definition 458
- evaluation and selection bias 456–8
- hidden biases 460–62
- matched sampling 460
- model of treatment choice 457
- model-based covariate adjustment 459, 460
- propensity score matching 459–60
- study designs 458–9
- self-assessed health (SAH) 21, 23, 29–30, 31
 - cultural differences 30
 - personal responsibility 384, 385–6
- Senegal
 - contracting-out 252
 - GATS commitments 168
- senior citizens *see* ageing; retirement
- sexual behaviour
 - erectile dysfunction drugs 118
 - sexually transmitted diseases 62, 69, 412
 - and substance abuse 40
 - unsafe 486
 - in young people 67, 68
 - see also* HIV
- Shackley, Phil 247, 392–402, 405
- sibutramine (weight-loss drug) 78
- Sierra Leone, GATS commitments 168
- Sindelar, Jody L. 83–92
- skin complaints 200
- sleep apnoea 77
- sleep patterns 11
- Slovak Republic, GATS commitments 168
- Slovenia, GATS commitments 168
- Smith, Peter C. 223, 292, 317–25, 328, 330, 335, 517
- Smith, Richard 164–75, 237, 392, 394
- smoking 10, 11, 36–7, 41
 - and body weight 66
 - cost-effective analysis 480–86, 488–9
 - early behaviour 42–3
 - and price 65–6
 - and young people 62, 63, 64–5, 66, 67, 68
- snob effects 62–3
- social health insurance
 - administrative costs 130–31, 132
 - competitive 129–30, 132
 - cream-skimming 129–30, 132
 - economics of 126–36
 - efficiency reasons 126–7
 - equity reasons 127–8
 - future challenges 133–4
 - and government re-election 128, 129, 132
 - health redistribution 128–9
 - international purchasing 134
 - loss, non-insurable 131
 - medical care redistribution 128
 - moral hazard 129, 131–2
 - optimal design 130–31
 - public choice reasons 128–9
 - public health insurer 130, 132
 - rationing 132–3
 - risk assessment 126, 127, 129, 130, 131, 132, 134
 - supply of 129–30
 - technology changes 134
 - ‘umbrella’ policies 134
 - wealth redistribution 128
 - welfare gains 127
- social isolation 12
- social security 26–7, 214, 255
- socioeconomic status (SES) 18–19, 20, 21, 22
 - and early life conditions 33
 - and health and health care inequalities 179, 385–6
 - and health and health care inequities *see* equity
 - surveys, limits of 197, 206
- Somanathan, Aparnaa 193, 205–18
- South Africa
 - contracting-out 252, 255, 256, 257
 - GATS commitments 168
 - health services trade 170
 - providers, temporary movement of 171
 - public health intervention 54
- South America
 - cost-effective analysis on alcohol and tobacco use 480–86, 488–9
 - see also* individual countries
- South Korea
 - health care financing 212
 - health care utilization 208
- Southeast Asia
 - public health intervention 54
 - see also* individual countries
- Spain
 - hospital competition 221
 - macroeconomic effects on mortality 9
 - Panel Study 23, 24
 - smoking 65
- Sri Lanka
 - child mortality 51, 58, 207
 - equity in health care 205
 - FDI 170
 - government social spending 209, 211
 - health care financing 212, 214
 - health care utilization 208
 - health inequalities 206
 - poverty and health care expenditure 212, 213
 - tax systems, predominant 214–15

- state dependence 20–21, 27
 Stinnett, A. 499, 504, 515, 528, 534
 Street, Andrew 223, 292, 317–25, 330, 331, 335
 Street, Deborah J. 386, 415–26
 streptomycin 48
 stress 11
 strokes 77, 364, 366
 and physician experience on the treatment of 339
 substance use *see* drug use
 suicide
 and economic instability 5, 7, 8
 and young people 62, 67
 supplier-induced demand 39–40
 Sutton, Matt 181, 193–204, 373–4
 Swaziland, GATS commitments 168
 Sweden
 GATS commitments 168
 health care use 149
 hospital competition 221, 228
 inequalities in self-reported health 181
 (PES) Public Employment System data 29
 prescribing behaviour 309
 providers, temporary movement of 171
 public health expenditure 221
 Swedish Obese Subjects (SOS) study 78
 unemployment 29
 Switzerland
 alcohol and price 65
 child mortality 49
 GATS commitments 168
 health insurance 112
 health plans 221, 285
 hospital competition 228
 performance measurement 332
 public health expenditure 221
 social health insurance 130
 Taiwan
 cross-border supply of services 167
 health care financing 211, 212, 214
 health care use 207
 health care utilization 208
 poverty and health care expenditure 213
 social security systems 214
 Tan-Torres Edejer, Tessa 479–91
 Tanzania
 health care workers 53
 public health intervention 55
 technology changes 134
 technophysio-evolution 48, 51
 testicular cancer, and QALY model 349
 tetanus 57
 Thailand
 government social spending 209
 health care financing 212, 214
 health care utilization 208
 health services trade 170
 poverty and health care expenditure 213
 tax systems, predominant 214–15
 Thompson, Robin 156–63, 215
 thyroid problems 120
 time preference rates 18
 time series analysis 5–6
 Torrance, G.W. 360, 361, 362, 373, 375
 tourism 170, 173
 see also migration
 traffic deaths 7, 8, 9
 and alcohol 10
 and young people 62, 68
 traffic safety, risk reduction 392
 transition countries
 hospital stays, length of 161
 unofficial health care economy 156, 157, 161
 see also individual countries
 Trinidad and Tobago, GATS commitments 168
 Trivedi, Pravin K. 147–55
 Tsuchiya, Aki 129, 382–91, 541
 tuberculosis 52, 57, 251, 486
 Turkey, GATS commitments 168
 typhoid 52, 54
 Uganda
 contracting-out 252, 256
 health care workers 53
 unofficial health care economy 156
 UK 23, 24, 31
 bargaining in health care 237, 238
 BHPS (British Household Panel Survey) 19, 20, 21, 23
 child mortality 49
 contracting-out 250, 253
 cost effective analysis 495, 499, 537–9
 day case treatment 199–202
 distributional judgements 385
 District Health Authorities 227
 drug-related crime 83
 equity in health care consumption in England 199–203
 ethnicity 199–203
 EuroWill project 398
 financial incentives 289, 292
 fixed price contracts 246
 GP consultations 199–202, 203
 GP (general practitioner) fundholding 117–18, 119, 227, 238, 271, 274

- health resource group (HRG) 246, 248
- health services trade 170
- hospital competition (England) 221, 223, 226–7, 228
- hospital waiting times 238
- in-patient stays 199–202
- inequalities in self-reported health 181
- London Patient Choice Project (LPCP) 227
- National Health Service 126, 238, 246, 289, 499
- National Health Service Act 95
- NHS Health Technology Assessment Programme 384
- NHS ‘internal market’ 226–7
- NICE (National Institute for Health and Clinical Excellence) 397, 410–11, 495, 499, 500, 514, 516, 524, 537–8, 540, 542, 543–4
- out-patient visits 199–202, 203
- performance measurement 326, 330, 331
- pharmaceuticals evaluation 537–8, 540, 542, 543–4
- PPS (prospective payment system) 246
- prescribing cost reduction 227
- Primary Care Trusts 272, 274
- providers, temporary movement of 171, 172
- public health expenditure 221
- public-private partnerships 239
- quality assessment 361
- quality incentive programme 289
- smoking 65
- technology assessment 514, 516, 524
- transport safety policy 399
- willingness to pay 399
- ulcers, and advertising 310
- UN Millennium Development Goals (MDGs) 251
- unemployment 6, 7, 8, 9, 10, 18
 - Germany 32
 - insurance 31
 - Sweden 29, 30
- Uruguay, child mortality 50
- USA
 - ‘any willing provider’ laws 235
 - bargaining in health care 237
 - BBA (Balanced Budget Act) 297
 - Boren Amendment 297
 - calorie consumption 73–4
 - Canada, importing drugs from 114, 121
 - capitation payments 265–6, 271–2
 - child mortality 50
 - child mortality decline 48
 - DCA (direct to consumer advertising) 306–8, 309–10, 311–12
 - diagnosis related group (DRG) 246, 248
 - Drug Policy Alliance 83
 - drug smuggling 88
 - drug subsidies to seniors 115
 - drug use 83, 84, 87
 - drug-related crime 83, 85
 - financial incentives 288–9
 - fixed price contracts 246
 - GATS commitments 167, 168
 - health insurance 32, 99, 102, 147
 - health maintenance organizations (HMOs) 117, 118, 119, 120, 233, 237, 238, 264, 266, 271, 527
 - health plans 138, 142, 143, 144, 147, 221, 271, 281–2, 284, 287, 288, 326
 - and health services trade 170
 - HEDIS (Health Plan Employer Data Information Set) 326, 331, 332
 - height of men 48, 51
 - hospital competition 223, 224, 226
 - income levels 11
 - Leapfrog Group for Patient Safety 288
 - legal drinking age 84
 - life expectancy 453
 - macroeconomic effects on mortality 6–8, 9, 10, 11
 - managed care industry 144
 - marijuana use 83
 - Medicaid *see* Medicaid
 - medical costs 450
 - Medicare *see* Medicare
 - MEPS-IC (Medical Expenditure Panel Survey – Insurance Component) 145
 - mortality rates 330
 - National Health Interview Survey 72
 - NSDUH (National Survey on Drug Use and Health) 84
 - nursing home care 296–305, 340
 - obesity 72–3, 78, 79
 - OBRA87 (Omnibus Budget Reconciliation Act) 299
 - Olmstead Decision, Supreme Court 298
 - ‘orphan drug’ treatments 527
 - OSCAR reporting system 299
 - outpatient visits 149
 - ‘pay-for-performance’ schemes 267
 - payment rate freezes 265
 - performance measurement 324, 326, 330, 331–2
 - PPS (prospective payment system) 246, 297, 301–2
 - prescribing behaviour 309–10
 - prescription drugs 83, 84
 - providers, temporary movement of 172
 - PSID (Panel on Income Dynamics) 19

- public health expenditure 221
 RAND Health Insurance Experiment (HIE)
 99, 109–10, 131, 151, 286, 440
 retirement 27
 Robert Wood Johnson Foundation 289
 self-reported disability 30
 smoking 65, 66
 Social Security Act Amendments 97–8
 surgical success rates 324
 USAID 256
 value-based purchasing 288
 water quality 52
- vaccination 52, 53, 54, 57–8, 452
 and performance measurement 332
see also immunization
- van Doorslaer, Eddy 22, 23, 179–92, 193, 194,
 207, 208, 212, 213
- Vanness, David J. 514, 526–36
- vector control 55, 57
- Venezuela, unofficial health care economy 159
- Vietnam
 child health and maternal services 209
 child malnutrition 180–81
 child mortality 51, 58, 186, 207
 head-for-age z-scores for children (HAZ)
 181, 182, 185, 186, 187, 188–90
 health care use 150
 health financing 215
 health inequalities 185–6
 poverty and health care expenditure 212, 213
 transition economies 215
- Viney, Rosalie 386, 405, 415–26
- vitamin A
 in cereals 52
 supplementation 48, 55, 57, 58
- Wagstaff, Adam 5, 21, 23, 129, 179–92, 193,
 194, 207, 208, 212, 213, 251
- waiting lists, and globalization 173
- waiting times 225, 227, 238, 323
- water quality 47, 52, 55, 486
- weight
 and appearance 79
 behavioural theory of 76–7, 80
 BMI (body mass index) 66, 72–3, 75, 78
 capital investment model of 74
 and food prices 75–6, 77
 and income 75
 loss 78
 neoclassical theory of 74–6
 sibutramine (weight-loss drug) 78
 and smoking 66
 and technology 75
see also diet; obesity
- Weinstein, Milton C. 447, 469–78, 493, 494,
 495, 505, 508
- WHO (World Health Organization) 53, 55, 57,
 129, 206, 320
 CHOICE (Choosing Interventions that are
 Cost-Effective) project 486
 health definition 371–2
 Health InterNetwork 167
 International Classification of Impairment,
 Disabilities and Handicaps 372
 league tables 324
 Williams, A. 24, 194, 196, 198, 320, 384, 492,
 493, 497, 500, 541
 willingness to pay (WTP) 392–9, 403, 406, 410
- Wilson, Deborah 248, 292, 319, 324, 326–34,
 335
- workforce
 inexperienced 11
 older 26–35
see also employment
- World Bank Health Sector Priorities Review
 486
- World Health Organization *see* WHO
- WTO (World Trade Organization) 165
- WTP (willingness to pay) 392–9, 403, 406, 410
- Yellow Fever 55
- young people
 alcohol use 62, 64, 65, 66, 67, 68–9
 death, leading causes of 62
 health behaviours among 62–71
 maternal employment, effects of 67–8
 NLSY (National Longitudinal Survey of
 Youth) 67, 68, 75
 obesity 62, 66
 peer and parental pressure 62–4, 66–8
 price pressure 62–6
 ‘rotten kids’ model 64
 and sexual behaviour 67, 68
 and smoking 62, 63, 64–5, 66, 67, 68
 and suicide 62, 67
 and traffic deaths 62, 68
- Zambia
 GATS commitments 167, 168
 hospital competition 228
 public health intervention 55
- Zero Tolerance laws 68–9
- Zweifel, Peter 126–36, 149

